Gyre Therapeutics (GYRE) Operating Income Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.05% |
| Dec 31, 2025 | 15.05% |
| Sep 30, 2025 | 19.43% |
| Jun 30, 2025 | 16.27% |
| Mar 31, 2025 | 19.61% |
| Dec 31, 2024 | 15.41% |
| Sep 30, 2024 | 18.34% |
| Jun 30, 2024 | 17.31% |
| Mar 31, 2024 | 20.24% |
| Dec 31, 2023 | -50.97% |
| Sep 30, 2023 | 28.69% |
| Jun 30, 2023 | 21.97% |
| Mar 31, 2023 | 24.55% |
| Dec 31, 2022 | -30.97% |
| Sep 30, 2022 | 2.55% |
| Jun 30, 2022 | 60.56% |
| Mar 31, 2022 | -28.65% |
| Dec 31, 2021 | -31.23% |
| Sep 30, 2021 | -34.59% |
| Jun 30, 2021 | -32.29% |
| Mar 31, 2021 | -37.46% |
| Dec 31, 2020 | -32.10% |
| Sep 30, 2020 | -32.89% |
| Jun 30, 2020 | -51.14% |
| Mar 31, 2020 | -10.82% |
| Dec 31, 2019 | -50.73% |
| Sep 30, 2019 | -51.78% |
| Jun 30, 2019 | -45.44% |
| Mar 31, 2019 | -53.18% |
| Dec 31, 2018 | 2.57% |
| Sep 30, 2018 | 8.69% |
| Jun 30, 2018 | 10.64% |
| Mar 31, 2018 | 4.19% |
| Dec 31, 2017 | 18.55% |
| Sep 30, 2017 | 6.21% |
| Jun 30, 2017 | -19.31% |
| Mar 31, 2017 | -32.61% |
| Dec 31, 2016 | 12.44% |
| Sep 30, 2016 | 9.35% |
| Jun 30, 2016 | -13.84% |
| Mar 31, 2016 | -18.85% |
| Dec 31, 2015 | -28.11% |
| Sep 30, 2015 | -29.25% |
| Jun 30, 2015 | -19.56% |